Stocks
Evolent Health Financial Statements (EVH) |
||||||||||
| Evolent Healthsmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 04.05.2023 | 03.08.2023 | 02.11.2023 | 23.02.2024 | 10.05.2024 | 10.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 427.7 | 469.1 | 511.0 | 556.1 | 639.7 | 2 176 | |||
| Operating Income, bln rub | -1.79 | -21.6 | -17.9 | -21.4 | 5.83 | -55.0 | ||||
| EBITDA, bln rub | ? | -37.4 | 27.5 | 29.5 | 26.7 | 35.3 | 119.1 | |||
| Net profit, bln rub | ? | -20.0 | -34.3 | -25.3 | -33.4 | -17.3 | -110.3 | |||
| OCF, bln rub | ? | -7.97 | 0.654 | 60.5 | 89.4 | 4.91 | 155.5 | |||
| CAPEX, bln rub | ? | 9.06 | 6.85 | 6.79 | 6.05 | 5.35 | 25.0 | |||
| FCF, bln rub | ? | -17.0 | -6.19 | 53.7 | 83.3 | -0.438 | 130.4 | |||
| Dividend payout, bln rub | 3.65 | 4.88 | 5.10 | 5.16 | 5.08 | 20.2 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18.3% | ||||
| OPEX, bln rub | 119.0 | 122.5 | 129.0 | 111.0 | 68.8 | 431.3 | ||||
| Cost of production, bln rub | 310.5 | 351.9 | 386.6 | 454.4 | 565.1 | 1 758 | ||||
| R&D, bln rub | 6.70 | 6.80 | 6.60 | 6.60 | 6.30 | 26.3 | ||||
| Interest expenses, bln rub | 12.9 | 14.5 | 14.6 | 12.2 | 6.00 | 47.3 | ||||
| Assets, bln rub | 2 589 | 2 647 | 2 670 | 2 680 | 2 644 | 2 644 | ||||
| Net Assets, bln rub | ? | 1 122 | 1 093 | 1 096 | 1 068 | 1 048 | 1 048 | |||
| Debt, bln rub | 632.3 | 695.8 | 653.6 | 644.8 | 824.4 | 824.4 | ||||
| Cash, bln rub | 157.5 | 142.5 | 184.5 | 192.8 | 216.7 | 216.7 | ||||
| Net debt, bln rub | 474.8 | 553.3 | 469.0 | 452.0 | 607.6 | 607.6 | ||||
| Ordinary share price, rub | 32.5 | 30.3 | 27.2 | 33.0 | 32.8 | 24.0 | ||||
| Number of ordinary shares, mln | 107.8 | 111.3 | 112.3 | 113.6 | 114.1 | 114.1 | ||||
| Market cap, bln rub | 3 498 | 3 372 | 3 057 | 3 752 | 3 743 | 2 736 | ||||
| EV, bln rub | ? | 3 972 | 3 925 | 3 526 | 4 204 | 4 350 | 3 344 | |||
| Book value, bln rub | -822 | -826 | -799 | -801 | -800 | -800 | ||||
| EPS, rub | ? | -0.19 | -0.31 | -0.23 | -0.29 | -0.15 | -0.97 | |||
| FCF/share, rub | -0.16 | -0.06 | 0.48 | 0.73 | 0.00 | 1.14 | ||||
| BV/share, rub | -7.63 | -7.43 | -7.12 | -7.05 | -7.01 | -7.01 | ||||
| EBITDA margin, % | ? | -8.75% | 5.87% | 5.78% | 4.81% | 5.52% | 5.48% | |||
| Net margin, % | ? | -4.67% | -7.32% | -4.96% | -6.01% | -2.70% | -5.07% | |||
| FCF yield, % | ? | -0.03% | -0.34% | 1.81% | 3.03% | 3.48% | 4.77% | |||
| ROE, % | ? | -2.97% | -5.81% | -8.30% | -10.6% | -10.5% | -10.5% | |||
| ROA, % | ? | -1.29% | -2.40% | -3.41% | -4.22% | -4.17% | -4.17% | |||
| P/E | ? | -104.9 | -53.1 | -33.6 | -33.2 | -33.9 | -24.8 | |||
| P/FCF | -3 522 | -290.4 | 55.1 | 33.0 | 28.7 | 21.0 | ||||
| P/S | ? | 2.36 | 2.07 | 1.71 | 1.91 | 1.72 | 1.26 | |||
| P/BV | ? | -4.25 | -4.08 | -3.83 | -4.68 | -4.68 | -3.42 | |||
| EV/EBITDA | ? | -80.5 | -110.4 | 196.6 | 90.6 | 36.5 | 28.1 | |||
| Debt/EBITDA | -9.62 | -15.6 | 26.2 | 9.74 | 5.10 | 5.10 | ||||
| R&D/CAPEX, % | 74.0% | 99.3% | 97.2% | 109.1% | 117.8% | 105.0% | ||||
| CAPEX/Revenue, % | 2.12% | 1.46% | 1.33% | 1.09% | 0.84% | 1.15% | ||||
| Evolent Health shareholders | ||||||||||
